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by Elsevier B.V. This is an open accesAbstract Tuberculosis (TB) is one of the leading causes of morbidity and mortality world-
wide, with ever increasing resistance to commonly used antituberculous drugs. Drug-
resistant TB was recognized shortly after the introduction of an effective therapy in the late
1940s, the use of streptomycin, which was the first widely used antituberculosis drug. Patients
who received this drug usually had marked and rapid clinical improvement, but treatment fail-
ures were common after the first three months of therapy. Most children are infected by
household contacts who have TB, particularly parents or other caretakers. Common symptoms
of pulmonary TB in children include cough (chronic, without improvement for more than three
weeks), fever (higher than 38 C for more than two weeks), and weight loss or failure to thrive.
Findings on a physical exam may suggest the presence of a lower respiratory infection,
whereas the clinical presentation of extra pulmonary TB depends on the site of disease. The
most common forms of extra pulmonary disease in children are TB of the lymph nodes and
of the central nervous system. The role of inadequate treatment and poor compliance in
the emergence of resistance highlights the importance of the DOT (Direct Observation Ther-
apy) method in improving treatment outcomes and to control the spread of resistance.
Copyright ª 2016, King Faisal Specialist Hospital & Research Centre (General Organization),
Saudi Arabia. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
TB is a disease that is caused by the bacterium Mycobac-
terium tuberculosis. The bacteria usually attack the lungs,
but TB bacteria can attack any part of the body, such as the
kidney, spine, or brain. If not treated properly, TB can be
fatal. TB was once the leading cause of death.509410010.
.com (G.I. AL Qurainees).
f King Faisal Specialist Hospital &
15.11.003
al Specialist Hospital & Research C
s article under the CC BY-NC-ND2. Case presentation
A 7-year-old Saudi girl presented to the emergency
department at this tertiary care hospital with a worsening
course of fever, cough, weight loss, and abdominal pain
over 3 weeks. She was admitted to a local hospital earlier
and was suspected of having lymphoma. There was a historyResearch Centre (General Organization), Saudi Arabia.
entre (General Organization), Saudi Arabia. Production and hosting
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1 Clinical investigation upon diagnosis and during
treatment of DOT.
Laboratory data On
diagnosis
On DOT Normal
range
CBC and differential
WBC, 109/L 19.17 5.86 4.30e11.30
RBC, 1012/L 3.49 4.34 4.30e5.50
hemoglobin, g/L 67 113 110e150
Hematocrit, L/L 0.294 0.339 0.350e0.450
MCVfL 73.7 78.1 75e95
MCHCpg 22.5 26 24e30
RDW, % 19 12.9 11e15
Platelet, 109/L 25 231 155e435
Neutrophil
absolute, 109/L
6.20 1.71 1.35e7.50
Lymphocyte
absolute, 109/L
1.21 2.88 1.90e4.90
ESR, mm/h 140 9 0e15
CRP, mg/L 103 0.4 3 mg/L
Albumin, g/L 17 42.9 32e48
AST, U/L 373 33.5 10e45
ALT, U/L 114 24.9 10e35
Bilirubin, total, umol/L 6.3 4.9 0e21
Alkaline phosphate, u/L 269.5 246 100e300
HIV 1e2 antibody
screening
Non
reactive
A child with Mycobacterium tuberculosis 29of recent contact with an aunt who was diagnosed as having
pulmonary TB 6 months earlier and who was started on
treatment with 4 drugs. The results of culture and sus-
ceptibility testing are not available. The child’s place of
residence in AL-Jouf was crowded, with many extended
family members, and was poorly ventilated. Her father was
45 years old, and her mother was 35 years old. Both were
healthy, but of poor socioeconomic status.
On examination, the child looked acutely ill, pale,
tachypneic, and tachycardic, with a temperature of
39.6 C, WT 11.7 < 5th centile, and HT 106 cm > 50th
centile. There were multiple cautery marks over the chest
wall and upper abdomen, and on chest auscultation, there
was a marked decrease of air entry on the right side, with
bronchial breathing and basal crepitations.
2.1. Laboratory data (Table 1)
The chest X-ray (Fig. 1) demonstrated an airspace disease
involving the right lower lobe and a cystic change involving
the right upper lobe with blunted cardiopulmonary angles.
A CT scan of the chest (Fig. 2) demonstrated large airspace
consolidation involving the right middle and lower lobes,
with a large cavity in the right upper lobe, and bilateral
miliary nodules that had a tree-in-bud appearance. There
were multiple mediastinal necrotic lymph nodes suggestive
of acute on top of chronic TB. The abdominal CT showed
small hypo-dense splenic lesions.
Based on these findings, the patient was diagnosed as
having pulmonary TB, iron deficiency anemia, and failure to
thrive. Air borne isolation was initiated, and she was
admitted to a negative air pressure room and started on
INH, Rifampicin, pyrazinamide streptomycin, pyridoxine,
and iron therapy. Four days after treatment, her platelet
count decreased to 25 x 109/L.
Rifampicin-induced thrombocytopenia was suspected,
and the drug was therefore discontinued and replaced with
ethambutol. Subsequently, the platelet count rebounded to
a normal level.Figure 1 Airspace disease involving the right middle and lowThe Mantoux test was positive. Sputum for the AFB stain
was positive, and the rapid DNA amplification test was
positive for the M. tuberculosis complex. The culture was
later reported to be positive for mycobacterium TB. The
isolate was susceptible to streptomycin, isoniazid,
rifampin, ethambutol, and pyrazinamide.
The general condition of the patient improved on treat-
ment, with a normalizing respiratory rate and other vital
signs, but she experienced persistent episodes of low-grade
fever. Her appetite improved, with good oral intake ander lobe with a cystic change involving the right upper lobe.
Figure 2 Improvement of the airspace disease in the right middle and lower lobe after starting treatment. Bronchial wall
thickening with peribronchial infiltrates in the perihilar region.
30 G.I. AL Qurainees, H.T. Tufenkejiincreasedweight. The baseline eye examinationwas normal,
and follow ups were arranged. After 18 days of inpatient
treatment, the patient was discharged, due in part to the
insistence of the parents for an early discharge, on etham-
butol, INH, Pyrazinamide, a Streptomycin IM injection once
daily for 8 weeks (to be given at a local hospital), iron ther-
apy, and pyridoxine with a follow-up OPD appointment.
On frequent repeated outpatient visits over the ensuing
months, the response to treatment was suboptimal, as
evidenced clinically and according to the investigation re-
sults. Poor compliance was suspected, and her antimicro-
bial serum levels were found to be undetectable. The local
treating physician was contacted, and arrangements were
made to initiate direct observation therapy (DOT); howev-
er, the family did not agree to have health care personnel in
their home. This ultimately resulted in her clinical deteri-
oration and a second admission.
At this admission, there was a history of fever with chills
for one month associated with decreased oral intake and
activity. The parents noticed that she developed cervical
and sternal ulcers, which were progressively worsening and
discharging yellow, milky material.Figure 3 Improvement in the miliary nodules as well as the endo
middle lobe after starting treatment.On examination, she was conscious, listless, unwell in
appearance, pale, and dehydrated. Her vital signs were as
follows: temperature: 38.4 C, heart rate: 147 beats per
minute, respiratory rate: 28 per minute, O2 saturation: 100% in
room air, and blood pressure: 87/48 mmHg. A chest exam
showed clear vesicular breathing, with no added sounds and
decreased air entry, mainly on the right side. A cardiovas-
cular exam showed normal S1 and S2, with no murmur. The
abdomen was mildly distended with no organomegaly. She
had multiple ulcerative skin lesions on the right side of the
neck, over the sternum, and chest as well as bilateral
axillary lymph nodes, which were ulcerating and discharg-
ing milky serous material. Her hemoglobin was 5 g/dl,
indicating poor nutrition and poor compliance with all
medications, including iron therapy.
She was admitted with the impression of pulmonary and
extra pulmonary (scrofuloderma) TB secondary to poor
compliance withmedical therapy in addition to social issues.
The patient received packed RBCs. A review of the cultures
and susceptibility results of the specimens from the sputum
and lesions taken earlier showed that the organism had
become first resistant to INH, then to ethionamide andbronchial tree-in-bud involvement of the right upper lobe and
Figure 4 Chest CT: Large airspace consolidation involving
the right middle and lower lobes with cavitary areas, a large
cavity in the right upper lobe, bilateral miliary nodules and
tree-in-bud appearance, with multiple mediastinal necrotic
lymph nodes.
A child with Mycobacterium tuberculosis 31streptomycin. The patient was therefore started on etham-
butol, pyrazinamide, cycloserine, moxifloxacin, and pyri-
doxine (vitamin B6) to reduce the risk of the neurotoxicity of
cycloserine and iron therapy. A specimen was submitted to a
specialized center abroad, and PZA was tested by broth
dilution using critical concentrations and CLSI interpretive
criteria. All other agents were tested by the microbroth
dilution with the (minimal inhibitory concentration) MIC re-
ported and using laboratory developed interpretive criteria.
The blood culture was negative. The wound culture was
positive for Streptococcus pneumonia and for MRSA, which
were treated accordingly. C-reactive protein was 239. A CT
chest scan with contrast (Fig. 3) showed an interval increase
in the number, size, and necrosis of the previously seen
enlarged cervical and axillary lymph nodes, with abscess
formation in addition to patchy pneumonic consolidations of
the upper,middle, and right lower lobes. A bone scan showed
mild increased activity in the left clavicle, likely related to a
chronic infectious process. However, according to Pediatric
Surgery, there was no role for surgical intervention.
The Child Advocacy Committee (CAC) was involved
because of obvious parental neglect in the form of poor
compliance with medications and refusal to cooperate with
local as well as this hospital’s medical staff. After several
sessions with the parents and in coordination with the local
Ministry of Health (MOH) authorities, an arrangement was
made for admission to a local hospital where the child
would receive her medications as an inpatient and then be
followed up later with DOT therapy along with appoint-
ments at our hospital for a total of at least 9 months.On outpatient follow-up, the patient continued on
ethambutol, pyrazinamide, cycloserine, moxifloxacin, pyr-
idoxine, and iron therapy. She has markedly improved, with
an absence of fever, weight gain, normal inflammatory
markers, and clearing CXR (Fig. 4), Table 1.3. Discussion
TB remains a significant global health problem, with nearly
9 million new cases and 1.5 million deaths estimated
annually [1,2]. The estimated incidence of TB in Saudi
Arabia is 14/100,000 [3]. Because of increased resistance to
commonly used anti-TB drugs, management has become
more complex and difficult, requiring the use of second-line
drugs and, in some cases, surgical resection. Drug-resistant
TB is defined as an infection caused by a strain of M.
tuberculosis that is resistant to one of the first-line anti-TB
drugs: isoniazid, rifampin, pyrazinamide, ethambutol, or
streptomycin. Multidrug-resistant TB (MDR-TB) is defined as
an infection caused by a strain of M. tuberculosis that is
resistant to at least isoniazid and rifampin. Extensively
drug-resistant TB (XDR-TB) is defined as an infection caused
by a strain of M. tuberculosis that is resistant to at least
isoniazid, rifampin, and fluoroquinolones, as well as either
aminoglycosides (amikacin and kanamycin), capreomycin or
both [4]. Totally drug-resistant TB (TDR-TB) is defined as an
infection caused by a strain of M. tuberculosis that is
resistant to all locally tested medications [5,6]. Primary
drug resistance is said to occur in a patient who has never
received anti-TB therapy, and secondary drug resistance
refers to the development of resistance during or following
chemotherapy in patients who had previously had drug-
susceptible TB.
The first representative national survey conducted in
Saudi Arabia showed that of 1904 patients, 79.3% had pul-
monary and 20% had extra pulmonary TB, with lymph nodes
being the most common site of infection (56.2%) [7]. Of the
1609 isolates from new cases of TB, 16.4% were resistant to
at least one first-line drug and 1.8% were MDR. Of the 295
isolates from previously treated TB cases, 63.4% were
resistant to at least one first-line drug and 15.9% were MDR.
The prevalence of resistance to anti-tuberculosis agents
was highest for INH followed by streptomycin and rifam-
picin. Regarding the geographical distribution of MDR-TB in
the country, the highest prevalence was detected in the
northern and southern provinces, followed by the western
and central provinces, and the lowest proportion was re-
ported in the eastern province.
The treatment of patients with INH monoresistant TB has
not been evaluated rigorously in randomized trials, and
therefore, approaches are generally based on expert
opinion derived from retrospective or single arm studies. In
general, most patients with INH monoresistance should be
treated with a rifamycin (rifampin or rifabutin), pyr-
azinamide, and ethambutol.
The duration of therapy should be six to nine months (or
four months after culture conversion) [8,9], based on trials
conducted by the Hong Kong Chest Service/British Medical
Research Council, which demonstrated success rates of
95e98% among 107 patients with INH-resistant disease [10].
This finding was also supported by a retrospective study of
32 G.I. AL Qurainees, H.T. Tufenkejipatients with INH-monoresistant TB treated for six months,
which showed comparable rates of failure or relapse among
patients with drug-susceptible TB [9].
Data supporting the addition of a fluoroquinolone for the
treatment of INH-monoresistant TB is inconsistent with one
study of 328 patients with smear-positive TB who were
randomized to receive either INH or moxifloxacin (in addi-
tion to rifampin, pyrazinamide, and ethambutol), in which
culture negativity after eight weeks was comparable be-
tween the two groups (55 and 60%, respectively) [11]. On
the other hand, a retrospective Danish study suggested that
the inclusion of a fluoroquinolone in the treatment regimen
was associated with a slightly higher success rate [12].
As per the World Health Organization (WHO) recom-
mendation, the treatment of patients for whom drug sus-
ceptibility testing is not available but are known to reside in
a region with a background level of INH resistance > 7%, an
acceptable approach consists of a standard initial phase
(e.g., INH, rifampin, pyrazinamide, and ethambutol), fol-
lowed by a continuation phase with INH and rifampin as
well as the addition of ethambutol (rather than only INH
and rifampin). Overall, effective therapy for INH-
monoresistant TB is associated with very high bacterio-
logic, clinical response rates (>95%), and low relapse rates
(<5%). National TB treatment guidelines strongly recom-
mend using a patient-cantered case management
approach, including directly observed therapy (“DOT”),
when treating persons with active TB. DOT is especially
critical for patients with drug-resistant TB, HIV-infected
patients, and those on intermittent treatment regimens
(i.e., 2 or 3 times weekly). DOT means that a trained health
care worker or other designated individual (excluding a
family member) provides the prescribed TB drugs and
watches the patient swallow every dose to ensure that the
medications are administered as directed. Because TB
treatment entails several drugs taken regularly for several
months, people from all social classes, educational back-
grounds, ages, genders, and ethnicities may find it difficult
to correctly adhere to the instructions. Studies show that
86e90% of patients receiving DOT complete therapy,
compared to 61% for those on self-administered therapy.
DOT helps patients finish TB therapy as quickly as possible,
without unnecessary gaps, prevents TB from spreading to
others, decreases the risk of drug-resistance resulting from
erratic or incomplete treatment and decreases the chances
of treatment failure and relapse [13e16].
Serious reactions to antituberculosis drugs are uncom-
mon. Rifampicin-induced thrombocytopenia is an uncom-
mon but potentially life-threatening complication of
antituberculosis treatment [17]. Rifampicin-induced
thrombocytopenia was first reported by Blajchman and
co-colleagues [18] in 1970. Most of the described cases
were observed with high dose intermittent therapy
(1200 mg twice weekly) [19]. Only a few cases of throm-
bocytopenia have occurred during daily treatment or after
the administration of rifampicin following an interruption
of therapy [18,20]. The Tuberculosis Research Centre of
Chennai reported only a single case of rifampicin-induced
thrombocytopenia among more than over 8000 patients
treated for tuberculosis over 30 years [21]. It has been
observed that rifampicin-induced thrombocytopenia is
caused by the presence of anti-rifampicin antibodies [20].These antibodies fix a complement on the platelets in the
presence of rifampicin, resulting in platelet destruction
[21]. It has been found that antibodies against rifampicin
are significant in number among patients who have stopped
therapy; yet, rifampicin-induced thrombocytopenia is still
relatively rare [18,21]. The low incidence of thrombocyto-
penia due to daily doses of rifampicin has been attributed
to the possible development of neutralizing antibodies
formed during continuous treatment or may occur because
the antigeneantibody complex is continuously removed
without causing an allergic reaction [22]. Thus, daily doses
of rifampicin may result in immunologic tolerance, whereas
intermittent dosing favors sensitization [23]. It has been
recommended that rifampicin-induced thrombocytopenia
be an absolute contraindication to further therapy with
rifampicin [19]. However, Bhasin and co-colleagues [24]
suggested that re-challenges should be performed before
withdrawing rifampicin. When it is necessary to re-start
rifampicin, one should check the platelets counts
frequently, under supervision and with the use of steroids.
We present this case as an example of a child with
complicated TB as illustrated by the initial poor clinical
response to therapy caused by the emergence of resis-
tance. On presentation, the organism cultured was sensi-
tive to all first line agents, but because of poor compliance
as documented by undetectable drug levels, the patient
developed polydrug resistance. The improvement in the
intake of medications and the resulting treatment success
in this case was undoubtedly achieved by following the DOT
method. Moreover, collaboration with the local physician
and health care authorities was key in the implementation
process. Confirmation of rifampicin-induced thrombocyto-
penia at the time of initial presentation is not often
possible because tests for drug-dependent anti-platelet
antibodies are not available in most laboratories. Discon-
tinuation of the suspected drug leading to the resolution of
thrombocytopenia provides strong evidence of rifampicin-
induced thrombocytopenia. TB is nearly always curable if
patients are treated with effective and uninterrupted
antituberculous therapy. In children, parental support and
an understanding of the importance of adherence to
treatment as instructed is critical in bringing about cure,
controlling the spread of infection, and minimizing the
development of drug resistance. In the U.S.A., a Task Force
composed of representatives of many federal agencies has
developed a National Action Plan for addressing MDR-TB.
The Task Force identified a number of objectives that must
be met if MDR-TB is to be successfully combatted. These
objectives fall under the categories of a) surveillance and
epidemiology to determine the magnitude and nature of
the problem; b) laboratory diagnostics to improve the
rapidity, sensitivity, and reliability of diagnostic methods
for MDR-TB; c) patient management to effectively man-
aging patients who have MDR-TB and to prevent patients
with drug-susceptible TB from developing drug-resistant
disease; d) screening and preventive therapy to identify
persons who are infected with or at risk of developing MDR-
TB and to prevent them from developing clinically active
TB; e) infection control to minimize the risk of transmission
of MDR-TB to patients, workers, and others in institutional
settings; f) outbreak control; g) program evaluation to
ensure that TB programs are effective in managing patients
A child with Mycobacterium tuberculosis 33and preventing MDR-TB; h) information dissemination/
training and education; and i) research to provide new
more effective tools with which to combat MDR-TB [25].
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